As of March 31, 2025, the U.S. Food and Drug Administration (FDA) has mandated that compounding pharmacies cease the production of compounded versions of tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound. The decision followed the FDA’s announcement that the shortage of these medications had been resolved, and it ends access to the less expensive compounded versions.
The change can affect both the price of treatment and how easy it is to get for people who use tirzepatide for diabetes or weight loss.
From Compounded to Brand-Name Tirzepatide
- The U.S Food & Drug Administration has stopped allowing compounded tirzepatide now that there is no longer a shortage of GLP-1 drugs like Mounjaro and Zepbound.
- Patients now need the brand-name medications, which can raise the cost of treatment considerably for both diabetes and weight loss.
- The FDA is back to its standard rules, which limit compounding when the approved drug is readily available.
- Patients should talk with their doctor and look into financial assistance programs to help with the higher cost.
- The Naderi Center is helping patients access treatment by offering guidance and cost-conscious options during this transition.
Why has Compounded Tirzepatide Ceased?
The FDA has ceased compounded tirzepatide following the stabilization of the national supply of GLP-1 medications, which includes tirzepatide. Once the shortage ended, the FDA’s temporary permission for compounders to make these drugs was no longer needed.
With brand-name drugs available again, the FDA has returned its focus to safety and regulatory compliance. Patients now receive manufacturer-produced tirzepatide that has gone through FDA testing for safety, effectiveness and quality.
The FDA also holds concerns regarding risks of dosing errors and side effects linked to unapproved GLP-1 drugs used for weight loss.
Book a Consultation
Thinking about weight loss treatment? Our physicians see patients at our offices in Reston, VA and Chevy Chase, MD.
Book a ConsultationLearn about weight loss treatment
Call Reston (703) 481-0002 or Chevy Chase (301) 222-2020.
What is The Impact on Patients?
The cessation of compounded tirzepatide means that patients seeking treatment for diabetes or weight loss will now need to obtain prescriptions for the brand-name medications. Costs are expected to rise, since compounded versions often sold for a fraction of the brand-name price. For instance, the brand-name drug Zepbound has a list price of approximately $1,059 per month without insurance coverage.
What to Do Next?
Patients affected by this change are encouraged to:
- Consult with their healthcare providers: Ask about alternatives, which could mean switching to another FDA-approved medication for weight loss or diabetes.
- Consult financial assistance: Brand-name GLP-1 medications usually cost more out of pocket than the compounded versions did. Ask about manufacturer savings cards, rebates or support programs that can make treatment more affordable.
- Staying informed about regulatory updates: The rules on these medications can keep changing. Following FDA updates helps you know what options are available and whether any new approvals could affect your treatment.
Secure Your Safe Treatment Experience with The Naderi Center
Join our satisfied clients who’ve experienced safe, effective treatments.
How will the Naderi Center help?
Because this change can be a real financial burden, The Naderi Center is working to help patients get these medications at a lower cost. As Dr. Naderi, the center’s founder, puts it:
“At The Naderi Center, we understand the challenges our patients face with the rising costs of weight loss medications like tirzepatide. Our team is dedicated to exploring all avenues to ensure that our patients continue to receive the treatments they need without undue financial strain.”
Consult with Board-Certified Specialists
Changing drug rules are hard to sort out on your own, so it helps to talk with a physician who follows them. Our physicians keep up with the current weight loss medications and their alternatives, and they can help you find a treatment that fits your health and your budget. Contact us to talk about your options.
See the Doctor
Questions about what you just read? Ask our doctors in person. Book a consultation in Reston or Chevy Chase, or start with a virtual consultation from home.
Book a ConsultationVirtual consultation
Call Reston (703) 481-0002 or Chevy Chase (301) 222-2020.
FAQs about FDA Cease Compounded Tirzepatide
Patient Financing
Pay Over Time with Cherry
Monthly payment plans for surgery and treatments, including 0% APR options for qualifying patients. Checking whether you qualify won’t affect your credit score.